Profile data is unavailable for this security.
About the company
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
- Revenue in USD (TTM)126.62m
- Net income in USD13.83m
- Incorporated2010
- Employees120.00
- LocationCytomX Therapeutics Inc151 Oyster Point Blvd., Suite 400SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 515-3185
- Fax+1 (650) 351-0353
- Websitehttps://cytomx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| X4 Pharmaceuticals Inc | 1.12m | -16.76m | 62.08m | 93.00 | -- | 1.04 | -- | 55.28 | -0.0853 | -0.0853 | 0.0056 | 0.3538 | 0.0064 | -- | 1.53 | 12,075.27 | -9.54 | -61.53 | -11.29 | -69.20 | 55.92 | -- | -1,492.34 | -13,288.93 | 4.80 | -- | 0.5579 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Immuneering Corp | 0.00 | -58.07m | 62.57m | 66.00 | -- | 1.14 | -- | -- | -1.97 | -1.97 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -63.66 | -- | -68.36 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Celularity Inc | 42.69m | -112.83m | 62.66m | 120.00 | -- | 2.25 | -- | 1.47 | -5.77 | -5.77 | 2.14 | 1.27 | 0.2236 | 3.92 | 4.65 | 355,750.00 | -59.09 | -19.19 | -90.61 | -20.99 | 60.24 | -- | -264.30 | -454.79 | 0.2182 | -11.18 | 0.5958 | -- | 26.68 | -- | -1,483.14 | -- | -- | -- |
| RetinalGenix Technologies Inc | 0.00 | -4.04m | 62.99m | 0.00 | -- | -- | -- | -- | -0.2291 | -0.2291 | 0.00 | -0.101 | 0.00 | -- | -- | -- | -9,059.05 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -1,050.46 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| Spero Therapeutics Inc | 106.46m | 3.51m | 64.32m | 46.00 | 19.54 | 0.9867 | 17.94 | 0.6042 | 0.0609 | 0.0609 | 1.97 | 1.21 | 0.8788 | -- | 3.78 | 2,314,239.00 | 2.90 | -35.52 | 4.19 | -41.75 | -- | -- | 3.30 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Allovir Inc | 0.00 | -100.20m | 65.86m | 112.00 | -- | 0.5433 | -- | -- | -0.8755 | -0.8755 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -54.04 | -52.85 | -59.58 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| Agenus Inc | 160.43m | -227.86m | 67.09m | 389.00 | -- | -- | -- | 0.4182 | -11.06 | -11.06 | 7.81 | -13.48 | 0.559 | -- | 259.38 | 412,408.80 | -81.56 | -55.02 | -663.00 | -115.31 | 99.61 | -- | -145.89 | -102.92 | -- | -0.7247 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Bioatla Inc | 11.00m | -81.82m | 67.20m | 65.00 | -- | 2.93 | -- | 6.11 | -1.70 | -1.70 | 0.2284 | 0.4751 | 0.103 | -- | -- | 169,230.80 | -76.61 | -48.72 | -103.22 | -57.35 | -- | -- | -743.79 | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| CytomX Therapeutics Inc | 126.62m | 13.83m | 67.81m | 120.00 | 5.17 | -- | 4.33 | 0.5356 | 0.1675 | 0.1675 | 1.52 | -0.2998 | 0.7031 | -- | 43.88 | 1,055,142.00 | 7.68 | -21.53 | 29.38 | -32.32 | -- | -- | 10.92 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| ALX Oncology Holdings Inc | 0.00 | -151.16m | 68.04m | 89.00 | -- | 0.4973 | -- | -- | -2.98 | -2.98 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -74.50 | -34.34 | -89.35 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0851 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Metagenomi Inc | 55.08m | -73.95m | 68.18m | 207.00 | -- | 0.2664 | -- | 1.24 | -2.51 | -2.51 | 1.67 | 6.83 | 0.1479 | -- | 24.41 | 233,389.80 | -19.86 | -- | -23.47 | -- | -- | -- | -134.27 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 69.59m | -- | 4.03 | 0.1408 | 35.99 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| Beyondspring Inc | 1.88m | -15.57m | 70.12m | 35.00 | -- | -- | -- | 37.38 | -0.3987 | -0.3987 | 0.0481 | -0.749 | 0.0698 | -- | -- | 52,111.11 | -59.75 | -75.50 | -102.15 | -96.48 | -- | -- | -856.29 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| Vistagen Therapeutics Inc | 875.70k | -39.57m | 70.44m | 45.00 | -- | 0.7362 | -- | 80.44 | -1.30 | -1.30 | 0.0289 | 3.44 | 0.0121 | -- | -- | 22,453.85 | -54.69 | -62.84 | -58.94 | -68.03 | -- | -- | -4,518.12 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
| Aligos Therapeutics Inc | 6.00m | -76.95m | 71.00m | 68.00 | -- | 1.36 | -- | 11.84 | -18.70 | -18.70 | 1.12 | 14.53 | 0.0688 | -- | -- | 90,863.63 | -88.31 | -51.20 | -117.62 | -59.73 | -- | -- | -1,283.19 | -1,399.21 | -- | -- | 0.004 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -4.30m | 73.52m | 12.00 | -- | 8.95 | -- | -- | -0.3306 | -0.3306 | 0.00 | 0.6316 | 0.00 | -- | -- | 0.00 | -41.44 | -56.31 | -42.99 | -77.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 26.73 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to CytomX Therapeutics Inc's reporting currency: US Dollar USD
48.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 30 Sep 2024 | 7.81m | 10.00% |
| BVF Partners LPas of 30 Sep 2024 | 5.23m | 6.69% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 5.14m | 6.58% |
| Janus Henderson Investors US LLCas of 30 Sep 2024 | 4.81m | 6.16% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 3.10m | 3.97% |
| Prosight Management LPas of 30 Sep 2024 | 3.02m | 3.87% |
| Adage Capital Management LPas of 30 Sep 2024 | 3.00m | 3.84% |
| Millennium Management LLCas of 30 Sep 2024 | 2.56m | 3.28% |
| Assenagon Asset Management SA (Germany)as of 30 Sep 2024 | 1.64m | 2.11% |
| Jacobs Levy Equity Management, Inc.as of 30 Sep 2024 | 1.52m | 1.95% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
